Latest Blog Posts Tagged "Phase I Trial"
August 02, 2018
Denali will move its drug into trials with patients with or without a LRRK2 mutation after new research points to potential widespread use of these therapies.
December 20, 2016
Herantis Pharma was awarded a $6M grant to study the safety and efficacy of a potential therapy for Parkinson's disease (PD): cerebral dopamine neurotrophic factor (CDNF).
November 10, 2016
The trial showed the therapy is safe and tolerable and that the drug gets into the central nervous system well and reduces levels of alpha-synuclein in blood serum. Phase II expected to begin in 2017.
September 01, 2016
In the last few months, Cynapsus Therapeutics Inc. has announced Phase II results of its under-the-tongue strip to alleviate motor symptoms, FDA Fast Track Designation and a buyout.
December 16, 2014
Biotech AFFiRiS has begun a clinical trial for a new vaccine (PD03A) to treat Parkinson's. This builds on the success of the MJFF-funded trial of the company's first PD vaccine candidate (PD01A).
July 31, 2014
The Austrian biotech AFFiRiS AG announced positive results of its Phase I safety trial of a vaccine against alpha-synuclein, a treatment that could slow or stop Parkinson's disease .
June 05, 2012
Austria-based biotech and Michael J. Fox Foundation awardee AFFiRiS AG announced the launch of an early stage clinical trial of a first-of-its-kind vaccine approach to treating Parkinson's disease.